Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA
admin Biogen Inc. BIIB, -1.93% and Eisai Co. Ltd. 4523, +3.57% are getting closer to a…
Read MoreJP:4523
Getting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive…
Read MoreRegulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read MoreEisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read More